Cipla Limited (NSE: CIPLA)
India
· Delayed Price · Currency is INR | Market Cap | 1.30T |
| Revenue (ttm) | 258.92B |
| Net Income (ttm) | 43.03B |
| Shares Out | 807.56M |
| EPS (ttm) | 53.25 |
| PE Ratio | 30.25 |
| Forward PE | 28.08 |
| Dividend | 13.00 (0.81%) |
| Ex-Dividend Date | Aug 2, 2024 |
| Volume | 913,309 |
| Open | 1,627.75 |
| Previous Close | 1,627.75 |
| Day's Range | 1,608.05 - 1,631.95 |
| 52-Week Range | 1,132.00 - 1,681.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2024 |
About Cipla
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormaliti... [Read more]
Financial Performance
In 2023, Cipla's revenue was 255.37 billion, an increase of 13.20% compared to the previous year's 225.59 billion. Earnings were 41.22 billion, an increase of 47.10%.
Financial StatementsNews
Cipla’s M K Hamied steps down as VC
Read about Cipla's M K Hamied stepping down as Vice-Chairman due to age and health reasons. His son Kamil Hamied appointed as non-executive director. Expert views on leadership continuity.
Cipla, Bajaj Finance, and M&M lead Nifty gainers as pharma and finance stocks surge
The Indian stock market saw significant gains in select sectors on August 30, 2024, with pharmaceutical and financial stocks dominating the list of top performers in the Nifty index. Here’s a breakdow...